Report: Agreement between the US government and a major pharmaceutical company reveals pricing uncertainty.

Vontobel's Stefan Schneider wrote in a report that TrumpRx seems to mainly offer discounted low-volume drugs for uninsured people, but pricing for new drugs in the US is still unclear. The US government stated on Friday evening that they may reach agreements with nine major pharmaceutical companies including Roche and Novartis. However, the analyst stated that the terms of the agreements are still confidential, limiting deeper analysis. The discounts seem to be limited to Medicare plans, which already receive significant discounts. This means that its impact may not be as severe as if it included federal health insurance or all US sales. He added that this evolving process allows pharmaceutical companies to adjust prices elsewhere. Novartis and Roche's stock prices fell by 0.2% and 0.1% respectively.